The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China

Clinical Neuropharmacology

Volumn 39, Issue 2, 2016, Pages 81-87

  Chen, Hongxi ^a   Zhang, Yan ^a   Shi, Ziyan ^a   Feng, Huiru ^a   Yao, Shaoli ^a   Xie, Jinglu ^a   Zhou, Hongyu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Autoantibodies; Mycophenolate mofetil; Neuromyelitis optica; Neuromyelitis optica spectrum disorder; Prednisolone

Indexed keywords

ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; AUTOANTIBODY; MYCOPHENOLIC ACID;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHINA; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HAIR LOSS; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; BLOOD; DISABILITY; DOSE RESPONSE; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; NEUROMYELITIS OPTICA; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; CHINA; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUROMYELITIS OPTICA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84955610251     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000131     Document Type: Article

References (41)

1. Wildemann B, Jarius S. The expanding range of autoimmune disorders of the nervous system. Lancet Neurol 2013;12(1):22-24.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6(9):805-815.
3. Benavente E, Paira S. Neuromyelitis optica-AQP4: an update. Curr Rheumatol Rep 2011;13(6):496-505.
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-2112.
5. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53(5): 1107-1114.
6. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68(8):603-605.
7. Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012;18(10): 1480-1483.
8. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69(2): 239-245.
9. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18(1):113-115.
10. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010;67(9): 1131-1136.
11. Jeong IH, Park B, Kim SH, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 2015. [Epub ahead of print].
12. Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015;351(1-2):31-35.
13. Qiu W, Kermode AG, Li R, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 2015;22(7):1178-1182.
14. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014;71(3): 324-330.
15. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 2014;20(11): 1533-1540.
16. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77(7):659-666.
17. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51(4):1219-1220.
18. Kim SM, Park J, Kim SH, et al. Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One 2013;8(12):e82325.
19. Sahraian MA, Moinfar Z, Khorramnia S, et al. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 2010;17(6):794-799.
20. Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014;71(11): 1372-1378.
21. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128-1133.
22. Falcini F, Trapani S, Ricci L, et al. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford) 2006;45(7):913-915.
23. Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol 2014;14:51.
24. Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013;84(5): 511-516.
25. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68(4):473-479.
26. Yaguchi H, Sakushima K, Takahashi I, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 2013;52(9):969-972.
27. Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013;260(2):627-634.
28. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12(6): 554-562.
29. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 2015;72(7):756-763.
30. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66(10):1485-1489.
31. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007; 13(8):968-974.
32. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012;18(1):5-10.
33. Iyer A, Elsone L, Appleton R, et al. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014;47(3):154-161.
34. Fialho SC, Bergamaschi S, Neves FS, et al. Mycophenolate mofetil in primary Sjögren's syndrome: a treatment option for agranulocytosis. Rev Bras Reumatol 2012;52(2):297-299.
35. Alexander S, Fleming DH, Mathew BS, et al. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther Drug Monit 2014;36(4):423-432.
36. Lourdudoss C, Vollenhoven RV. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lupus 2014;23(3):299-304.
37. Jayarangaiah A, Sehgal R, Epperla N. Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)-a case report and review of literature. BMC Neurol 2014;14:200.
38. Akman-Demir G, Tüzün E, Waters P, et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 2011;258(3):464-470.
39. Yang Y, Huang DH, Wu WP, et al. The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica. J Clin Neurosci 2013;20(1): 94-98.
40. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81(14):1197-1204.
41. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012;9:14.